Price
No data yet.
Social Signal Score
Analyst Ratings
23 analystsRevenue
$3.58B-3.70%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Javier J. Rodriguez
- Sector
- Healthcare
- Industry
- Medical - Care Facilities
- Employees
- 78,000
- Beta
- 0.86
- Country
- US
- Piotroski score
- 8 / 9 (Strong)
- Altman Z-score
- 1.65
Financials
Revenue
$3.58B-3.7%Net Income
$222.93M+41.3%EBITDA
$673.91M+22.0%Free Cash Flow
$359.34M+57.3%EPS (diluted)
$3.40+325.0%Shares Outstanding (diluted)
65.50M-66.7%Operating Expenses
$408.70MCash & Debt
$566.30MReturn of Capital
$109.52MRevenue by Segment (annual)
$11.73BQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $13.64B | $746.80M | $10.06 |
| 2024 | $12.82B | $936.34M | $11.02 |
| 2023 | $12.14B | $691.53M | $7.62 |
| 2022 | $11.61B | $560.40M | $5.88 |
| 2021 | $11.62B | $978.45M | $9.30 |
| 2020 | $11.55B | $773.64M | $6.54 |
| 2019 | $11.39B | $810.98M | $5.29 |
| 2018 | $11.40B | $159.39M | $4.63 |
| 2017 | $10.88B | $663.62M | $3.52 |
| 2016 | $14.75B | $879.87M | $4.36 |
| 2015 | $13.78B | $269.73M | $1.27 |
| 2014 | $12.80B | $723.11M | $3.41 |
| 2013 | $11.76B | $633.45M | $3.02 |
| 2012 | $8.19B | $536.02M | $2.79 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from DVA's reported EPS growth of 10.4% a year over 13 years.
- EPS in 5 years
- $16.50
- Implied price
- $181.50
- Return from $161.03
- 2.4% a year
To earn 15.0% a year on these assumptions you'd need to buy at $90.24 — -44.0% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 7 | 9 | 11 | 13 | 15 |
|---|---|---|---|---|---|
| 0.4% | -14.9% | -10.5% | -6.9% | -3.7% | -0.9% |
| 5.4% | -10.7% | -6.1% | -2.2% | 1.1% | 4.0% |
| 10.4% | -6.4% | -1.6% | 2.4% | 5.9% | 9.0% |
| 15.4% | -2.2% | 2.8% | 7.1% | 10.7% | 13.9% |
| 20.4% | 2.0% | 7.3% | 11.7% | 15.5% | 18.8% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
50+11.11%Social Signal Score
Mentions (39)
- Newsprnewswire.com·5d ago·Neutral
DaVita Expands Availability of Advanced Dialysis Therapy to Every U.S. Center Expanded HD removes a broader range of toxins from the blood, with 95% of patients adopting the therapy within two weeks of nationwide rollout DENVER, Nov. 17, 2026 /PRNewswire/ -- DaVita today announced a major milestone in kidney care: Expanded hemodialysis (Expanded HD) is now available at every DaVita center in the U.S., giving patients nationwide access to an advanced therapy that removes more of the larger toxins…
View source ↗ - Newsmarketbeat.com·9d ago·Neutral
DaVita Expects Fewer Dialysis Treatments in Q4, but Higher Revenue per Visit Could Help Offset the Drop DaVita NYSE: DVA expects a meaningful sequential decline in dialysis treatments in the fourth quarter because of calendar effects, but higher revenue per treatment should help offset the impact, Chief Financial Officer Joel Ackerman said at the Wolfe Healthcare Conference.
View source ↗ - Newsseekingalpha.com·12d ago·Positive
DaVita Inc. (DVA) Presents at 8th Annual Wolfe Research Healthcare Conference Transcript DaVita Inc. (DVA) Presents at 8th Annual Wolfe Research Healthcare Conference Transcript
View source ↗ - Newsmarketbeat.com·12d ago·Negative
DaVita Sees Growth and Drug Savings Offsetting 2027 Reimbursement Pressure DaVita NYSE: DVA expects stronger dialysis treatment growth and pharmaceutical cost savings to help offset reimbursement pressures in 2027, though Chief Financial Officer Joel Ackerman said changes in patients' insurance coverage will remain a significant headwind.
View source ↗ - News (RSS)seekingalpha·13d ago·Positive
DaVita Inc. (DVA) Presents at 2026 UBS Global Healthcare Conference Transcript
View source ↗ - Newsglobenewswire.com·13d ago·Negative
Lowey Dannenberg, P.C. is Investigating DaVita Inc. (NYSE: DVA) for Potential Violations of the Federal Securities Laws NEW YORK, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating DaVita Inc. (NYSE: DVA) (“DaVita” or the “Company”) for potential violations of the federal securities laws.
View source ↗ - Newszacks.com·17d ago·Neutral
Investors Heavily Search DaVita Inc. (DVA): Here is What You Need to Know DaVita HealthCare (DVA) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
View source ↗ - Newsprnewswire.com·19d ago·Neutral
DaVita Inc. to Participate in Upcoming Investor Conferences DENVER, Nov. 3, 2026 /PRNewswire/ -- DaVita Inc. (NYSE: DVA) today announced that its Chief Financial Officer, Joel Ackerman, and its Group Vice President of Investor Relations, Nic Eliason, will participate in fireside chats at the following upcoming investor conferences: UBS Global Healthcare Conference 2026 Date: Monday, November 9, 2026 Fireside Chat Presentation: 1:15 pm EST To view the live webcast, visit the UBS conference page a…
View source ↗ - Newszacks.com·23d ago·Positive
DaVita Q3 Earnings Beat Estimates on IKC Strength, Revenues Rise Y/Y DVA's Q3 earnings surge 52.2% as revenues rise 4.6%, fueled by strong kidney care and international growth despite rising costs and margin pressure.
View source ↗ - Newsmarketbeat.com·23d ago·Positive
What DaVita (DVA) Said on Its Q3 Earnings Call DaVita NYSE: DVA reported third-quarter adjusted operating income of $561 million, adjusted earnings per share of $3.82 and free cash flow of $276 million, while narrowing its full-year 2026 outlook. The kidney-care provider said its Integrated Kidney Care business outperformed expectations, though higher technology spending continued to weigh on U.S. dialysis results.
View source ↗ - Newsseekingalpha.com·24d ago·Positive
DaVita Inc. (DVA) Q3 2026 Earnings Call Transcript DaVita Inc. (DVA) Q3 2026 Earnings Call Transcript
View source ↗ - Newszacks.com·24d ago·Positive
DaVita HealthCare (DVA) Beats Q3 Earnings and Revenue Estimates DaVita HealthCare (DVA) came out with quarterly earnings of $3.82 per share, beating the Zacks Consensus Estimate of $3.78 per share. This compares to earnings of $2.51 per share a year ago.
View source ↗ - Newsprnewswire.com·24d ago·Neutral
DaVita Inc. 3rd Quarter 2026 Results DENVER, Oct. 29, 2026 /PRNewswire/ -- DaVita Inc. (NYSE: DVA) announced financial and operating results for the quarter ended September 30, 2026. Financial and operating highlights for the quarter ended September 30, 2026: Consolidated revenues were $3.578 billion.
View source ↗ - Newszacks.com·26d ago·Neutral
Will DaVita's Q3 Earnings Reflect Improving Treatment Growth Trends? DVA's Q3 2026 earnings are expected to rise on improving treatment volumes and cost discipline, but reimbursement pressures could weigh on profitability.
View source ↗ - Newsprnewswire.com·26d ago·Neutral
DaVita Brings Preventive Health Screenings Into Communities to Help Identify Hidden Health Risks Nearly 1,000 people screened in Houston and Los Angeles, with a majority showing signs of elevated chronic disease risk DENVER, Oct. 27, 2026 /PRNewswire/ -- Millions of Americans are living with chronic disease and don't know it. The risks are often interconnected: High blood pressure and diabetes can increase the risk of kidney disease, while chronic kidney disease (CKD) often progresses without sy…
View source ↗ - Newszacks.com·30d ago·Neutral
DaVita HealthCare (DVA) Falls More Steeply Than Broader Market: What Investors Need to Know DaVita HealthCare (DVA) closed at $183.64 in the latest trading session, marking a -1.32% move from the prior day.
View source ↗ - Newszacks.com·31d ago·Positive
DaVita Stock Gains 55.6% Year to Date: What's Behind the Rally? DaVita's 55.6% stock rally reflects stronger operating execution, improving treatment volumes and value-based kidney care gains despite reimbursement pressures.
View source ↗ - Newsprnewswire.com·34d ago·Neutral
DaVita Inc. Schedules 3rd Quarter 2026 Investor Conference Call DENVER, Oct. 19, 2026 /PRNewswire/ -- DaVita Inc. (NYSE: DVA), announced today that it will hold its quarterly conference call to discuss third quarter results on Thursday, October 29, 2026, at 5:00 p.m. Eastern Time.
View source ↗ - News (RSS)zerohedge·39d ago·Neutral
…ors, who said the bank "effectively outsourced" a key part of its compliance efforts as it sought to protect revenue (it then reported 3Q equities trading revenue ex-DVA of $2.51 billion, short of the $2.63 billion estimate, so not the best morning in Charlotte); BofA is also no longer part of the potential roster of banks working on Moonshot AI's IPO as the Chinese AI darling faces scrutiny in the US. Palliser Capital wants Samsung Electronics to list shares in the US and use the proceeds to bu…
View source ↗ - News (RSS)zerohedge·39d ago·Neutral
…ted EPS $1.08, missing estimate of $1.10; GAAP EPS $0.91 Revenue net of interest expense $29.96 billion, missing estimate of $30.76 billion Trading revenue excluding DVA $5.06 billion, missing estimate of $5.41 billion FICC trading revenue excluding DVA $2.55 billion, missing estimate of $2.86 billion Equities trading revenue excluding DVA $2.51 billion, missing estimate of $2.63 billion Net interest income $16.45 billion, beating estimate of $16.24 billion (NII FTE $16.61 billion) Net interest …
View source ↗ - News (RSS)seekingalpha·44d ago·Positive
DaVita: After A 25% Drop, The Buyback Machine Is Cheap Again
View source ↗ - Newszacks.com·44d ago·Neutral
Why DaVita HealthCare (DVA) Outpaced the Stock Market Today In the latest trading session, DaVita HealthCare (DVA) closed at $179.25, marking a +1.26% move from the previous day.
View source ↗ - Newsseekingalpha.com·44d ago·Positive
DaVita: After A 25% Drop, The Buyback Machine Is Cheap Again DaVita is rated Buy with a $220 12-month price target, offering 22% upside from current levels. Despite flat industry volumes and Medicare rate headwinds, DVA's aggressive buybacks drive most EPS growth, enhancing per-share value. At $180, DVA trades at 9.4x forward earnings, making buybacks more accretive and capital allocation more effective than at recent highs.
View source ↗ - Newszacks.com·44d ago·Positive
Here's Why You Should Retain DaVita Stock in Your Portfolio for Now DaVita gains from IKC growth, improving treatment economics and stronger formulary adoption, but payer-mix pressures and costs remain concerns.
View source ↗ - Newsprnewswire.com·45d ago·Positive
DaVita Activates Emergency Response Efforts Ahead of Hurricane Isaias, Urges Kidney Patients to Prepare Early Patients encouraged to confirm treatment schedules, prepare emergency supplies and contact DaVita for assistance DENVER, Oct. 8, 2026 /PRNewswire/ -- As Hurricane Isaias approaches the Gulf Coast and southeastern United States, DaVita has activated its emergency response plan to help patients continue receiving life-sustaining dialysis care and to support communities preparing for severe…
View source ↗ - Newszacks.com·51d ago·Negative
DaVita HealthCare (DVA) Laps the Stock Market: Here's Why In the closing of the recent trading day, DaVita HealthCare (DVA) stood at $178.69, denoting a +1.33% move from the preceding trading day.
View source ↗ - Newszacks.com·59d ago·Neutral
DaVita HealthCare (DVA) Registers a Bigger Fall Than the Market: Important Facts to Note The latest trading day saw DaVita HealthCare (DVA) settling at $174.67, representing a -4.62% change from its previous close.
View source ↗ - News (RSS)investing·66d ago·Positive
DaVita jumps 10% as AI strategy’s healthcare pick rides stronger guidance
View source ↗ - Newszacks.com·67d ago·Neutral
DaVita HealthCare (DVA) Advances While Market Declines: Some Information for Investors DaVita HealthCare (DVA) closed the most recent trading day at $193.86, moving +1.55% from the previous trading session.
View source ↗ - Newsgurufocus.com·69d ago·Positive
A Look at DaVita Inc (DVA) After 4.3% Gain -- GF Value $195.67 vs Price $189.32 On September 14, 2026, DaVita Inc (DVA) shares rose 4.3% to $189.32, reflecting strong momentum as the stock trades within a 52-week range of $101.00 to $247.49
View source ↗ - Newszacks.com·74d ago·Positive
Here's Why You Should Retain DaVita Stock in Your Portfolio for Now DVA gains from expanding value-based kidney care, improving dialysis volumes and clinical innovation, though payer-mix and regulatory risks persist.
View source ↗ - News (RSS)seekingalpha·78d ago·Neutral
Healthcare August recap: Moderna jumps 156% as biotech shines; DaVita sinks
View source ↗ - Newszacks.com·80d ago·Neutral
Do Options Traders Know Something About DaVita Stock We Don't? Investors need to pay close attention to DVA stock based on the movements in the options market lately.
View source ↗ - Newszacks.com·88d ago·Neutral
DVA & Humana Expand Value-Based Care for Kidney Disease Patients DaVita expands its Humana partnership to earlier-stage kidney disease, bringing value-based care to over 10,000 Medicare Advantage members.
View source ↗ - Newsprnewswire.com·88d ago·Neutral
Alebund Pharmaceuticals Announces 2026 Interim Results SHANGHAI, Aug. 26, 2026 /PRNewswire/ -- Alebund Pharmaceuticals (Jiangsu) Limited ("Alebund" or the "Company"; stock code: 09637.HK), a renal-focused biopharmaceutical company, today announced its unaudited consolidated interim results for the six months ended June 30, 2026 (the "Reporting Period"). During the Reporting Period and up to the date of the interim results announcement, the Company made significant progress on four fronts: clinic
View source ↗ - Newsprnewswire.com·89d ago·Neutral
DaVita Announces New Value-Based Partnership with Humana to Expand Care for Patients with Chronic Kidney Disease More than 10,000 members will get added support aimed at delaying or preventing dialysis and reducing hospitalizations DENVER, Aug. 25, 2026 /PRNewswire/ -- DaVita today announced a new value-based care agreement to deliver comprehensive, coordinated care to Humana Medicare Advantage members with chronic kidney disease (CKD) stages 3B–5. Launched July 1, this partnership builds on the…
View source ↗ - News (RSS)fortune·98d ago·Neutral
Berkshire Hathaway buys more homebuilder stocks but slashes stakes in banks and dumps all its holdings in alcoholic beverage maker Berkshire also reduced stakes in supermarket operator Kroger, steel manufacturer Nucor and dialysis giant DaVita.
View source ↗ - News (RSS)zerohedge·100d ago·Positive
…4.3MM shares added, or $118MMM, to $173.0MM Cuts: Bank of America (BAC), 30.2MM shares sold bringing total down to 483.4MM shares worth $27.5BN as of June 30 DaVita (DVA), 1.2MM shares sold bringing total to 28.9MM shares worth $6.4BN Kroger (KR), 11MM shares sold bringing total to 39MM shares worth $2.2BN Ally Financial (ALLY), 2MM shares sold bringing total to 27MM shares worth $1.2BN Capital One (COF), 4.2MM shares sold bringing total to 3MM shares worth $602MM Nucor (NUE), 2MM shares sold br…
View source ↗ - News (RSS)yahoo·103d ago·Positive
Are Wall Street Analysts Bullish on DaVita Stock?
View source ↗
Earnings
Mon, Feb 1(in 2 months)
Consensus estimate $4.13 per share
Typical surprise +4.9% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Oct 29$3.82 vs $3.57beat
- Tue, Aug 4$4.02 vs $3.88beat
- Tue, May 5$2.87 vs $2.41beat
- Mon, Feb 2$3.40 vs $3.24beat
- Wed, Oct 29$2.51 vs $3.17miss
- Tue, Aug 5$2.95 vs $2.70beat
Estimates and results for DVA via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by DVA officers and directors.
- Bought
- —
- Sold
- $523.4m
0 trades
13 trades
- Berkshire Hathaway Incsold
- Berkshire Hathaway Incsold
- Rodriguez Javiersold
- Waters Kathleen Alycesold
- Waters Kathleen Alycesold
- Rodriguez Javiersold
- Hearty James Osold
- Maughan David Paulsold
87 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Julie Johnsonhouse · TX32 · disclosed Aug 6, 2026 (317d later)Buy$1,001 - $15,000
- Julie Johnsonhouse · TX32 · disclosed Aug 6, 2026 (317d later)Sell$1,001 - $15,000
- Alan Armstrongsenate · disclosed Jul 21, 2026 (116d later)Buy$1,001 - $15,000
- Julie Johnsonhouse · TX32 · disclosed Oct 8, 2025 (13d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Oct 3, 2025 (28d later)Sell$1,001 - $15,000
- Jerry Moransenate · KS · disclosed Jan 17, 2024 (34d later)Sell$1,001 - $15,000
- Jerry Moransenate · KS · disclosed Jan 17, 2024 (34d later)Sell$1,001 - $15,000
- Thomas Hawley Tubervillesenate · AL · disclosed Jan 12, 2024 (31d later)Sell$1,001 - $15,000
- Thomas Hawley Tubervillesenate · AL · disclosed Jul 14, 2023 (32d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Jul 11, 2023 (12d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Jun 12, 2023 (24d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Apr 7, 2023 (14d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Mar 8, 2023 (22d later)Buy$1,001 - $15,000
- Jerry Moransenate · KS · disclosed Jan 21, 2022 (31d later)Sell$1,001 - $15,000
- Dean Phillipshouse · MN03 · disclosed Jun 13, 2019 (31d later)Sell$1,001 - $15,000
- Jerry Moransenate · KS · disclosed May 15, 2019 (160d later)Buy$1,001 - $15,000
- Jerry Moransenate · KS · disclosed May 15, 2019 (160d later)Buy$1,001 - $15,000
- Gilbert Cisneroshouse · CA39 · disclosed Apr 16, 2019 (33d later)Sell$1,001 - $15,000
- Dean Phillipshouse · MN03 · disclosed Mar 21, 2019 (45d later)Buy$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
